Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Articular Cartilage Defect: later-stage trial registry
2 of 3 indexed Articular Cartilage Defect trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Articular Cartilage Defect: 3 US clinical trials tracked, 2 recruiting.
Articular Cartilage Defect is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Vericel Corporation, running 2 of these trials.
Enrollment posture brief
Registry condition articular-cartilage-defect
OPEN 2 | RECR 67% | LATE 3 | EARLY 0 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Articular Cartilage Defect lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Articular Cartilage Defect on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Articular Cartilage Defect is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Vericel Corporation
NCT06915233
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Vericel Corporation
NCT03588975
NOVOCART 3D Treatment Following Microfracture Failure
Aesculap Biologics
NCT03219307
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Articular Cartilage Defect records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Articular Cartilage Defect trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Articular Cartilage Defect page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Articular Cartilage Defect trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vericel Corporation sponsors the most Articular Cartilage Defect trials on record, review their full trial history before evaluating a specific study. See Vericel Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Articular Cartilage Defect condition card totals 3 registered trials; most-linked intervention Novocart 3D; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.